Economic Burden of Alzheimer’s Disease Dementia in Japan

Abstract

Background: Alzheimer’s disease dementia (ADD) is the leading cause of long-term care in Japan. Objective: This study estimates the annual healthcare and long-term care costs in fiscal year 2018 for adults over 65 years of age with ADD in Japan and the informal care costs and productivity loss for their families. Methods: Healthcare and long-term care costs for ADD were estimated according to the disease severity classified by the clinical dementia rating (CDR) score, using reports from a literature review. For the costs of time spent on caregiving activities, productivity loss for ADD family caregivers aged 20–69 and informal care costs for all ADD family caregivers were estimated. Results: The total healthcare cost of ADD was JPY 1,073 billion, of which 86% (JPY 923 billion) was attributed to healthcare costs other than ADD drug costs (JPY 151 billion). The healthcare costs other than ADD drug costs by severity were less than JPY 200 billion for CDR–0.5, CDR-1, and CDR-2, respectively, but increased to JPY 447 billion (48%) for CDR-3. The public long-term care costs were estimated to be JPY 4,783 billion, which increased according to the severity. Total productivity loss for ADD family caregivers aged 20–69 was JPY 1,547 billion and the informal care cost for all ADD family caregivers was JPY 6,772 billion. Conclusion: ADD costs have a significant impact on public-funded healthcare, long-term care systems, and families in Japan. To minimize the economic burden of ADD, prolonging healthy life expectancy is the key factor to address.

Multimorbidity and catastrophic health expenditure: Evidence from the China Health and Retirement Longitudinal Study

“…Similarly, the need of continuous rehabilitation care for stroke patients also imposes a heavy financial burden on households ( 43 ). In many countries with aged populations, memory-related disease conditions such as dementia have resulted in rapid growth of health and care burdens ( 44 , 45 ).…”

The impact of social isolation from COVID-19-related public health measures on cognitive function and mental health among older adults: A systematic review and meta-analysis

“…Dementia is a clinical syndrome associated with loss of memory, language, problem-solving and other abilities that severely interferes with daily life, creating significant burdens not only for older adults with dementia but also their caregivers ( Brodaty and Donkin, 2009 , Cheng, 2017 , Sörensen and Conwell, 2011 ), and national health systems ( Department of Health, 2015 , Dharmarajan and Gunturu, 2009 , Ikeda et al, 2021 , Shon and Yoon, 2021 ). Global estimates suggest that the incidence of dementia will increase from 10 million new cases every year in 2020 to 78 million and 139 million by 2030 and 2050, respectively (Alzheimer's Disease International, n.d.).…”

Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel

“…Due to the scarcity of studies in the field, we compared this study's findings to those of other neurodegenerative diseases: Alzheimer's disease (AD)-another tau based neurodegenerative disease, and PD, the most common misdiagnosis in PwPSP [4,22]. Both conditions demonstrated an increase of medical expenditure with disease progression [23][24][25][26][27][28][29][30]. Whereas PD's direct costs were approximately US$ 6000 for patients with mild-moderate PD and US$ 7400 [29] for patients with advanced disease (median disease duration: 4 years), and PSP's direct costs were approximately US$ 10,000 and US$ 18,000 at the first diagnosis and fourth year after diagnosis, respectively.…”